From Yahoo Finance: 2025-05-13 08:53:00

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is highlighted as one of the top low-priced biotech stocks to buy now. Michael Yee of Jefferies discusses how tariffs and policy risks affect the sector, with estimated negative impacts of -4-5% EPS. Despite challenges, many biotech stocks are down 20-30% and offer buying opportunities. Hedge funds show interest in IOVA, projecting a triple increase in stock price. The company reported strong fiscal Q1 2025 earnings, with total revenue at $49.3 million. Despite a net loss, IOVA maintains a solid cash position of $366 million and plans for international market expansion. Analysts maintain a Buy rating on IOVA, expecting a price target of $10.00.



Read more at Yahoo Finance: Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now